IPIC Message Board - Msg: 4126163

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC

IPIC 0.0001000

0.0%

Aug 15 3:35 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margaret foley who wrote (1172)	4/20/1998 9:38:00 AM
From: Todd N. Weisrock	Read Replies (1) of 1359

This can't be good! I'm out... Dow Jones Newswires -- April 20, 1998 Interneuron CerAxon Trial Doesn't Meet Main Endpoints LEXINGTON, Mass. (Dow Jones)--Interneuron Pharmaceuticals Inc. (IPIC) said a trial for CerAxon that included 100 patients with stroke failed to meet its primary and secondary endpoint, a preliminary analysis showed. In a press release Monday, Interneuron Pharmaceuticals said due to the failure to meet the primary and secondary endpoint, it is withdrawing its New Drug Application for CerAxon pending results of additional testing. The company said the trial didn't detect a difference in the reduction of infarct size, which was the primary endpoint, among patients with ischemic stroke who received 500 milligrams a day of CerAxon, compared with patients who received a placebo. For the principal secondary endpoint, the trial didn't show an improvement in neurological function among drug-treated patients compared with patients who received a placebo.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next